Gleason score | Clinical stage | % positive cores | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parameter | ≥8 | ≤7 | p value | HR | 95% CI | ≥IV | ≤III | p value | HR | 95% CI | ≥30% | <30% | p value | HR | 95% CI |
No. of patients | 63 | 130 | 27 | 166 | 50 | 143 | |||||||||
Median age (SD), years | 73.0 (7.1) | 69.5 (7.2) | 0.076 | 1.050 | 0.995–1.108 | 75.0 (7.3) | 70.0 (7.2) | 0.255 | 1.049 | 0.966–1.138 | 73.0 (7.4) | 70.0 (7.1) | 0.120 | 1.052 | 0.987–1.121 |
Median serum PSA (95% CI), ng/mL | 32.1 (69.2-216.2) | 8.76 (12.3-20.2) | 0.001 | 1.022 | 1.009–1.036 | 55.9 (113.4-435.8) | 9.68 (16.5-27.9) | 0.010 | 1.009 | 1.002–1.017 | 52.8 (83.6-262.0) | 8.61 (9.6-24.8) | 0.005 | 1.017 | 1.005–1.030 |
Median prostate volume, mL | 27.0 (28.5-40.0) | 27.9 (28.8-34.0) | 0.387 | 0.991 | 0.970–1.012 | 33.2 (31.7-55.1) | 27.5 (28.3-32.8) | 0.057 | 1.024 | 0.999–1.049 | 28.4 (29.3-41.0) | 27.6 (28.6-34.1) | 0.164 | 0.982 | 0.957–1.007 |
Median concentration of T (95% CI) (blood) (/1000), pg/mL | 3.11 (2.90-3.62) | 3.64 (3.67-4.14) | 0.012 | 0.706 | 0.538–0.926 | 3.21 (2.56-4.06) | 3.61 (3.56-3.96) | 0.354 | 0.839 | 0.579–1.216 | 3.12 (2.84-3.74) | 3.66 (3.62-4.06) | 0.113 | 0.78 | 0.575–1.060 |
Median concentration of DHT (95% CI) (tissue), pg/mg | 5.31 (6.15-10.27) | 7.31 (9.26-13.02) | 0.222 | 0.974 | 0.935–1.016 | 4.68 (3.94-11.16) | 7.28 (9.04-12.18) | 0.756 | 0.992 | 0.942–1.044 | 5.26 (4.86-7.32) | 7.58 (9.77-13.46) | 0.003 | 0.878 | 0.806–0.956 |
Median concentration of T (95% CI) (tissue), pg/mg | 0.90 (1.20-2.23) | 0.46 (0.68-1.09) | 0.041 | 1.388 | 1.013–1.900 | 2.03 (1.74-3.84) | 0.50 (0.72-1.06) | 0.002 | 1.713 | 1.227–2.391 | 1.03 (1.42-2.70) | 0.47 (0.67-1.02) | 0.001 | 2.432 | 1.425–4.148 |